Converge Bio

Converge Bio: Generative AI for Drug Development

Converge Bio is a generative-AI platform that accelerates drug development from discovery through manufacturing. It applies AI to design and screen antibodies, optimize gene expression across cell systems, and discover targets and biomarkers through cellular simulation — compressing steps that traditionally take wet-lab teams months. The platform is built for the data-sensitivity of pharma, with private handling and customers retaining full IP ownership of the molecules produced.

It targets the computational bottlenecks in the drug pipeline while keeping the science and the intellectual property in the customer's hands.

Key Features

• AI-driven antibody design and screening
• Gene-expression optimization across cell systems
• Target and biomarker discovery via cellular simulation
• Private, secure data handling with no reuse for training
• Full customer IP ownership of molecules
• Fully managed infrastructure and deployment

Ideal Use Case

Converge Bio fits biotech and pharma teams that want to accelerate discovery, molecule design, and process development with AI while keeping data private and retaining IP. It suits research organizations bottlenecked by the computational stages of the drug pipeline.

How Converge Bio differentiates

Converge Bio spans discovery to manufacturing with private data handling and full customer IP ownership, addressing the trust barriers that slow AI adoption in pharma. It raised a Series A led by Bessemer Venture Partners.

FAQ

What is Converge Bio? A generative-AI platform that accelerates drug development across discovery, design, and manufacturing.

Who owns the molecules? Customers retain full IP ownership of molecules produced on the platform.

Is data kept private? Yes — Converge Bio uses private, secure handling and does not reuse customer data for training.

Who backs Converge Bio? A Series A led by Bessemer Venture Partners.

tl;dr

Converge Bio is a generative-AI drug-development platform spanning discovery to manufacturing, with private data handling and full customer IP ownership, backed by a Series A led by Bessemer.